Archives
SN-38 Beyond TOP1: FUBP1–FUSE Binding Study
2026-09-16
A Biochemical Pharmacology study identified camptothecin and SN-38 as inhibitors of the FUBP1–FUSE DNA-binding interaction, revealing a mechanism that may complement topoisomerase I inhibition. The work connects a biochemical screening assay with transcriptional changes in hepatocellular carcinoma cells and provides a rationale for testing FUBP1-dependent vulnerabilities in additional tumor models.
Thiazovivin (A5506): ROCK Inhibitor Workflow Guide
2026-09-15
Thiazovivin (A5506) is a ROCK inhibitor used to address poor cell recovery after dissociation and to support fibroblast reprogramming for induced pluripotent stem cell generation. This dossier-based guide covers preparation, controls, and troubleshooting for stem cell research; it is not a clinical, diagnostic, or universal dosing protocol.
Estradiol, ER Signaling, and CD4+ T-Cell Recovery
2026-09-15
This study identifies endoplasmic reticulum stress as a mechanistic link between hemorrhagic shock and impaired splenic CD4+ T-lymphocyte function. Its receptor-selective experiments indicate that estradiol restores immune-cell proliferation and cytokine production primarily through ERα and GPR30-associated signaling, rather than ERβ, providing a useful framework for studying post-traumatic immune dysfunction.
Cell Lysis Buffer for WB and IP in CAF Studies
2026-09-14
Discover how Cell lysis buffer for WB and IP supports native protein extraction, phosphoprotein preservation, and co-IP analysis in cancer-associated fibroblast research. This assay-focused guide translates the CAF–ANGPTL4–IQGAP1 findings into practical decisions for Western blot and immunoprecipitation workflows.
Chenodeoxycholic Acid: FXR Workflow & Uses
2026-09-14
Chenodeoxycholic Acid offers a practical way to connect FXR activation with transcriptional, inflammatory, and renal injury readouts. This guide translates recent CDCA–FXR–KLF11 findings into executable cell-based workflows, assay controls, and troubleshooting strategies for metabolic and kidney research.
Imatinib hydrochloride: Applied Kinase Research Workflows
2026-09-13
Build reproducible kinase-inhibition assays around Imatinib hydrochloride, from DMSO stock preparation to phospho-signaling and viability readouts. The workflow also translates a recent conformational-kinase study into practical controls without overstating what is established for imatinib.
AZD3463: ALK/IGF1R Inhibitor Workflow
2026-09-12
AZD3463 combines ALK and IGF1R pathway targeting with a practical workflow for mutation-aware neuroblastoma studies, pathway pharmacodynamics, and chemotherapy combinations. This guide translates the compound’s reported activity into reproducible setup, dosing, assay, and troubleshooting decisions while keeping evidence-backed findings separate from proposed optimization steps.
GDC-0994: ERK1/2 Inhibition Workflows
2026-09-11
GDC-0994 is a potent, selective ERK1/2 inhibitor for connecting pathway engagement with measurable changes in cancer-cell behavior and cholestatic liver injury. This workflow-focused guide covers formulation, phospho-ERK and phospho-p90RSK assays, zebrafish rescue experiments, comparative model selection, and practical troubleshooting.
Deferoxamine Mesylate for Iron-Stress Assays
2026-09-11
Deferoxamine mesylate gives researchers a practical way to separate iron-dependent oxidative injury from hypoxia signaling, ferroptosis, and repair phenotypes. This guide translates its solubility, chelation activity, and HIF-1α effects into reproducible cell, tumor, wound-healing, and radiation-response workflows.
V5 Epitope Tag Peptide: Kinetics to Assay Design
2026-09-10
The V5 Epitope Tag Peptide is more than a recognition sequence: it is a practical control for separating antibody specificity, binding kinetics, and assay performance. This guide connects the GKPIPNPLLGLDST peptide with evidence from single-molecule antibody screening and rigorous workflow design.
1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine Assays
2026-09-10
PP 3 provides a practical negative-control arm for experiments testing whether PP 2 effects truly depend on Src kinase activity. Its value is greatest in matched biochemical, cellular, and vascular workflows where DMSO exposure, concentration, timing, and orthogonal readouts are controlled rigorously.
SCH772984 HCl: Practical ERK1/2 Inhibition Workflows
2026-09-09
SCH772984 HCl is a nanomolar ERK1/2 inhibitor for dissecting MAPK-driven proliferation, resistance, and spatial translation. This guide connects cancer-focused workflows with cardiomyocyte assays inspired by recent findings on nuclear ERK and 4EBP1 phosphorylation, while emphasizing controls, timing, and troubleshooting.
2,2,2-Trichloroethanol: Reliable Protein Analysis
2026-09-09
Learn how 2,2,2-Trichloroethanol, SKU C6823, can support standardized protein electrophoresis and molecular biology workflows without being misrepresented as a direct cell-viability reagent. This scenario-based guide covers compatibility, handling, vendor selection, data interpretation, and limitations using product documentation and relevant translational research.
ICAA Targets RIP3 in Cardiac Hypertrophy
2026-09-09
A 2026 Cellular Signalling study identifies receptor-interacting protein 3 (RIP3) as a previously underappreciated regulator of angiotensin II- and pressure overload-induced cardiac hypertrophy. Its data position the RIP3/CaMKII axis, rather than the canonical RIP3/MLKL necroptosis pathway alone, as a mechanistic target of isochlorogenic acid A (ICAA).
Trametinib and Tumor Evolution in CRC Models
2026-09-08
Trametinib (GSK1120212) is more than a potent MEK1/2 inhibitor: it can serve as an evolution-aware oncology research tool for connecting ERK suppression with heterogeneous colorectal cancer responses. This article integrates its mechanism with patient-derived xenograft and multi-omics insights from metastatic CRC research.
606 records 8/41 page Previous Next First page 上5页 678910 下5页 Last page